Ben Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD
Show Description +
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.
Posted: 8/29/2024
Ben Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD
Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.
Posted: 8/29/2024
New Retina Radio is forging forward with education, and they’re partnering with Vit Buckle Society to make it happen. Check out these quick-hit reviews of journal articles delivered by VBS members.
New Retina Radio Journal Club with VBS: Switching to Faricimab in Wet AMD Patients With a History of Anti-VEGF Therapy
Ben Young, MD, MS; Lediana Goduni, MD; and Josh Uhr, MD
Please log in to leave a comment.